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Abstract The relationship between gains in bone mineral
density (BMD) in the hip and the incidence of vertebral
fractures in the MOVER study was examined. Japanese
patients from the ibandronate and risedronate treatment
groups whose hip BMD had increased during the 3-year
treatment period were classified into those with or without
vertebral fractures. In both the ibandronate group and the
risedronate group, hip BMD gains in the patients who had
developed no vertebral fractures during the treatment per-
iod were greater than in the patients who developed ver-
tebral fractures. We categorized the gains in hip BMD at
6 months into 3 groups (B0, [0 to B3, and [3 %), and
used logistic regression analysis to estimate odds ratios and
the probabilities of incidence of vertebral fractures at 12,
24, and 36 months. The current study demonstrated that
greater gains in hip BMD during the first 6 months of
treatment were associated with a reduction in the risk of
subsequent vertebral fractures during the duration of
treatment, and suggested that measurement of hip BMD
gain at that time could lead to a prediction of the risk of the
future vertebral fracture incidence.
Keywords Ibandronate  Vertebral fracture  Hip BMD
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Introduction
In the treatment of osteoporosis, bisphosphonates have
demonstrated their clinical efficacy, particularly their anti-
fracture efficacy, and have become the most widely used
anti-osteoporotic drugs worldwide. The anti-fracture effi-
cacy of ibandronate was first demonstrated in the BONE
study (oral iBandronate Osteoporosis vertebral fracture
trial in North America and Europe) that examined treat-
ment with oral ibandronate (2.5 mg/day and 20 mg inter-
mittently) [1]. The MOBILE study (Monthly Oral
iBandronate In LadiEs) was conducted to assess gains in
bone mineral density (BMD) with oral ibandronate (100
and 150 mg/month) [2]. The DIVA study (Dosing Intra-
Venous Administration) was also conducted to assess gains
in BMD with quarterly intravenous (IV) ibandronate
injection (3 mg/3 months) [3]. Analysis of pooled data
from the MOBILE and DIVA trials showed that, for all
clinical fractures, non-vertebral fractures, and clinical
vertebral fractures, there was a significantly longer time to
fracture events in the ibandronate group than in the placebo
group over 5 years [4]. Meta-analyses of the clinical
studies also demonstrated that ibandronate had significant
efficacy with respect to the risk reduction of not only key
non-vertebral fractures but also of all non-vertebral frac-
tures and clinical fractures [5, 6].
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The relationship between increases in BMD and fracture
risk reduction has been examined in meta-analyses of
ibandronate. The increase in BMD in the lumbar spine over
2 years showed a reverse relationship with the incidence of
clinical fractures, and the increase in hip BMD was asso-
ciated with a reduction in the risk of non-vertebral fractures
[7]. Gains in hip and lumbar spine BMD were also asso-
ciated with a reduction in vertebral fracture risk, explaining
a substantial proportion of the anti-fracture effect of
ibandronate (23–37 % at 2 and 3 years) [8]. In fact, it has
been reported elsewhere that decreased BMD is strongly
associated with increased fracture risks and that increased
BMD is predictive of the anti-fracture efficacy of treatment
[9].
The MOVER study (MOnthly intraVenous ibandronatE
versus daily oral Risedronate) was conducted for registra-
tion purposes in Japan [10]. The primary endpoint was the
non-inferiority of ibandronate versus risedronate to prove
its efficacy with respect to the incidence of non-traumatic
vertebral fractures at 3 years. Since the anti-fracture effi-
cacy of risedronate had been already demonstrated in
randomized comparative studies [11–13], risedronate was
selected as a suitable active comparator in the MOVER
study. The incidence rate of first new or worsening verte-
bral fractures was 16.1 % in the IV ibandronate 1 mg/
month treatment group and 17.6 % in the oral risedronate
2.5 mg/day treatment group at 3 years. The hazard ratio of
IV ibandronate 1 mg against risedronate was 0.88 (95 %
confidence interval [CI] 0.61–1.27). Significant increases
in BMD were observed in ibandronate 1 mg group as
compared to the risedronate group. Based on the efficacy
and safety data, monthly IV ibandronate 1 mg was
approved for the treatment of osteoporosis in Japan. The
current analysis from the MOVER study was conducted to
examine the relationship between changes in hip BMD and
the incidence of vertebral fractures, especially the impact
that initial BMD gains have on the future incidence of
vertebral fractures.
Materials and Methods
The design of the MOVER study is already described [10].
Briefly, 1,265 patients with primary osteoporosis diagnosed
according to the Diagnosis Criteria of Primary Osteopo-
rosis in Japan [14] were randomized. The per-protocol
population for the endpoint analysis comprised 376
patients in the ibandronate 0.5 mg group, 382 in the
ibandronate 1 mg group, and 376 in the risedronate group
(totally 1,134 patients). Baseline patient characteristics
were well balanced between the treatment groups
(Table 1). Morphometric vertebral fractures were assessed
using semiquantitative methodology and quantitative
morphometry by a central committee. BMD in lumbar




collagen equivalent, BMD bone
mineral density, CR creatinine,
SD standard deviation, uCTX
creatinine-corrected urinary
collagen type 1 cross-linked
C-telopeptide, uNTX creatinine-








Women, n (%) 356 (94.7) 354 (92.7) 343 (91.2)
Mean age, years (SD) 72.9 (6.34) 72.2 (6.38) 73.0 (6.29)
Aged 60–74 years, n (%) 219 (58.2) 245 (64.1) 227 (60.4)
Aged C 75 years, n (%) 157 (41.8) 137 (35.9) 149 (39.6)
Mean weight, kg (SD) 50.6 (8.00) 50.9 (7.36) 51.1 (8.35)
Mean height, cm (SD) 149.2 (6.66) 149.5 (6.56) 149.4 (6.70)
Mean BMD T-score (SD)
Lumbar spine (L2–L4) -2.71 (1.01) -2.68 (1.01) -2.59 (1.06)
Femoral neck -2.48 (0.73) -2.41 (0.80) -2.53 (0.79)
Total hip -2.17 (0.87) -2.09 (0.86) -2.18 (0.86)
Prevalent vertebral fractures, n (%)
1 186 (49.5) 184 (48.2) 183 (48.7)
2 97 (25.8) 106 (27.7) 95 (25.3)
[2 93 (24.7) 92 (24.1) 98 (26.1)
Mean uCTX, lg/mmol CR
(SD)
382.4 (226.2) 368.6 (209.9) 373.2 (261.0)
Mean uNTX, nM BCE/mM CR
(SD)
73.6 (39.31) 69.4 (35.42) 68.9 (35.16)
Mean BALP, IU/L (SD) 33.6 (13.15) 33.9 (13.11) 32.4 (11.96)
Mean 25-OH vitamin D,
ng/mL (SD)
19.6 (6.44) 20.0 (6.69) 19.7 (6.56)
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spine (L2–L4) and total hip was centrally measured at
baseline, 6, 12, 24, and 36 months using dual-energy X-ray
absorptiometry (DXA) of Hologic and Lunar bone densi-
tometers. In the current study, the patients in the ibandro-
nate 1 mg group and the risedronate group were sorted by
whether or not they developed vertebral fractures over the
3 years of treatment. The increase in BMD in the hip
during the treatment period was examined to characterize
its correlation with the anti-vertebral fracture efficacy of
the drugs. Estimation of odds ratios and probabilities of
developing vertebral fractures were performed based on
logistic regression analysis. A separate logistic regression
analysis was conducted for each of the treatment groups,
and the dependent variable was the occurrence of fractures
(with fractures) or non-occurrence of fractures (without
fractures) during each of the treatment periods, while the
independent variables included the change in hip BMD at
6 months (B0, [0 to B3, or [3 %), number of existing
fractures at screening (1 vs. C2 fractures), age at baseline
(\75 vs. C75 years), change in adjusted urinary C-telo-
peptide levels at 6 months, and change in bone-specific
alkaline phosphatase levels also at 6 months. Using the
estimated regression parameters and the data of the indi-
vidual subjects considered for the estimation of those
parameters, the probability of fractures in each subject was
calculated. This analysis was performed using SAS Ver-
sion 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Increase in hip BMD in Patients Without/With
Vertebral Fractures
The mean gains in BMD at 6 months relative to baseline in
the ibandronate 1 mg and risedronate treatment groups were
1.7 and 1.3 % in the hip and 5.1 and 3.9 % in the lumbar
spine, respectively, in the MOVER study [10]. Among
patients receiving IV ibandronate 1 mg, the mean changes in
hip BMD (Fig. 1a) in the group without vertebral fractures
were 1.9 ± 3.2 % (mean ± SD) (n = 305) at 6 months,
2.9 ± 3.3 % (n = 290) at 1 year, 3.6 ± 3.3 % (n = 265) at
2 years, and 3.5 ± 3.4 % (n = 242) at 3 years. Among
patients receiving IV ibandronate 1 mg, the mean changes in
hip BMD in the group with vertebral fractures were
0.7 ± 4.9 % (n = 48) at 6 months, 1.2 ± 3.7 % (n = 47)
at 1 year, 1.5 ± 4.4 % (n = 42) at 2 years, and
1.5 ± 5.0 % (n = 37) at 3 years. Among patients receiving
oral risedronate 2.5 mg, the mean changes in hip BMD
(Fig. 1b) in the group without vertebral fractures were
1.5 ± 3.1 % (n = 290) at 6 months, 2.3 ± 3.3 %
(n = 276) at 1 year, 2.3 ± 3.7 % (n = 251) at 2 years, and
2.2 ± 3.5 % (n = 228) at 3 years. Among patients
receiving oral risedronate 2.5 mg, the mean changes in hip
BMD in the group with vertebral fractures were
0.4 ± 4.9 % (n = 60) at 6 months, 1.2 ± 5.4 % (n = 59)
at 1 year, 1.5 ± 5.3 % (n = 53) at 2 years, and
1.5 ± 5.9 % (n = 49) at 3 years. In both treatment groups,
the increases in hip BMD were substantially greater at all
measurement times in the groups without vertebral fractures
than in the groups with fractures.
Future Vertebral Fracture Incidence Predicted
by Changes in Hip BMD at 6 months
The gains in hip BMD at 6 months were categorized into 3
groups (B0, [0 to B3, and [3 %). The probability of
incidence of vertebral fractures in these 3 groups was
estimated at 12, 24, and 36 months (Fig. 2a, ibandronate;
Fig. 2b, risedronate). In the ibandronate group, the median
probabilities of developing vertebral fractures at 12 months
in each of the 3 groups were 9.5 % (n = 80), 4.6 %
(n = 144), and 3.2 % (n = 114), respectively. In the
risedronate group, the median probabilities of developing
vertebral fractures at 12 months were 14.0 % (n = 113),
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Fig. 1 Mean increases (?SD) in total hip BMD in (a) ibandronate-
treated patients with (Black circle) or without (Black square)
vertebral fractures; (b) risedronate-treated patients with (White circle)
or without (White square) vertebral fractures
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median probabilities of developing vertebral fractures at
24 months were 16.8 % (n = 77), 9.2 % (n = 136), and
5.1 % (n = 109) in the 3 ibandronate groups and 18.8 %
(n = 111), 11.2 % (n = 133), and 8.6 % (n = 85) in the 3
risedronate groups, respectively. The median probabilities
of developing vertebral fractures at 36 months were
21.4 % (n = 72), 10.5 % (n = 128), and 8.9 % (n = 102)
in the 3 ibandronate groups and 25.3 % (n = 100), 16.7 %
(n = 119), and 13.0 % (n = 78) in the 3 risedronate
groups, respectively. The numbers of vertebral fracture
events that actually occurred (Table 2) were comparable to
the probabilities of future vertebral fractures estimated by
the logistic regression analysis.
The odds ratios for each group with a positive BMD
response ([0 to B3 % increase from baseline, and [3 %
increase) against the group with inadequate BMD response
(B0%) were compared for BMD gains in the hip and in the
lumbar spine in the first 6 months of treatment (Table 3).
With respect to the BMD gains in the hip, although the
ratios were mostly numerically lower in the ibandronate
group than in the risedronate group, it was shown that the
BMD gains in the hip at 6 months promised similarly
effective reduction in the risk of future vertebral fracture.
The gains in BMD in the femoral neck showed similar
trends in reduction of risk of future vertebral fracture (data
not shown). With respect to the BMD gains in the lumbar
spine at 6 months, the odds ratios were higher in the
risedronate group than in the ibandronate group.
Discussion
The purpose of this analysis of the MOVER study was to
examine the relationship between gains in BMD and the
occurrence of vertebral fractures by analyzing the gains in
hip BMD in the initial 6 months and the subsequent
development of vertebral fractures over time.
First, we compared the hip BMD gains in ibandronate-
or risedronate-treated patients who developed vertebral
fractures with those who had not developed vertebral
fractures during the 3 years of treatment. In both the
ibandronate and the risedronate treatment groups, hip BMD
gains were greater in the patients who developed no ver-
tebral fractures during the treatment period than in the
patients who developed vertebral fractures. The hip BMD
gains in the fracture-negative ibandronate group were
consistently greater than in the fracture-negative risedro-
nate group. On the other hand, both fracture-positive
groups showed similarly low BMD gains. These results
suggested that hip BMD gains could be an effective
parameter with which to predict the future incidence of
vertebral fractures.
Next, we categorized the patients into 3 groups
according to the gains in hip BMD in the first 6 months of
treatment, and we used logistic regression analysis to
estimate future vertebral fracture risk reduction at 12, 24,
and 36 months. Greater gains in hip BMD at 6 months
were associated with a greater reduction in the risk of
subsequent non-traumatic vertebral fractures over the
3-year treatment period. The BMD gains in the hip at
6 months, which might be the time-point when the effects
of bisphosphonates begin to be seen [15], were shown in
our analysis to predict the risk of vertebral fracture inci-
dence. In all treatment periods, the probability of devel-
oping vertebral fractures tended to be lower in groups that
had hip BMD gains of greater than 3 % than in those that
had lesser gains in hip BMD. The numbers of fracture
events also decreased according to the gain in BMD. The
odds ratios in the hip BMD gains were low overall—under
1 over the 3 years—and the values decreased according to
the BMD gains in the both treatment groups. Those results
might explain why hip BMD gains might predict the future
risk reduction of vertebral fracture. With respect to the
BMD gains in the lumbar spine at 6 months, the odds ratios
Fig. 2 Estimated probability of incidence of vertebral fractures
according to gains in hip BMD in patients treated with ibandronate
(a) and risedronate (b) at 12 months (left column), 24 months
(middle), and 36 months (right). The upper and lower fences
represent the maximum and minimum values, respectively. The box
represents the interquartile range. The cross indicates the mean value
and the horizontal line indicates the median value
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in the risedronate group were higher (but not significantly
higher) than in the ibandronate group. It is recently
reported that a bisphosphonate which has a lower mineral
binding affinity such as ibandronate or risedronate could be
efficiently delivered to the cortical bone area. It might be
one of explanations that ibandronate showed the greater
gains of BMD in the hip in a short period of 6 months [16,
17]. It has been also reported that the changes in lumbar
spine BMD by treatment with risedronate contributed only
18 % (95 % CI 10, 26 %) of its efficacy against vertebral
Table 2 Numbers of vertebral fracture events according to change in hip BMD at 6 months
Treatment Ibandronate Risedronate
Hip BMD at 6 months
B0 % [0 to B3 % [3 % B0% [0 to B3 % [3 %
(Months) (n = 85) (n = 150) (n = 118) (n = 116) (n = 145) (n = 89)
12 10 (12.5 %) 9 (6.3 %) 6 (5.3 %) 18 (15.9 %) 16 (11.6 %) 8 (9.3 %)
24 14 (18.2 %) 12 (8.8 %) 7 (6.4 %) 23 (20.7 %) 17 (12.8 %) 8 (9.4 %)
36 19 (26.4 %) 17 (13.3 %) 12 (11.8 %) 27 (27.0 %) 22 (18.5 %) 11 (14.1 %)
Treatment Ibandronate Risedronate
Lumbar spine BMD at 6 monthsa
B0 % [0 to B3 % [3 % B0 % [0 to B3 % [3 %
(Months) (n = 44) (n = 81) (n = 236) (n = 61) (n = 100) (n = 190)
12 3 (7.7 %) 5 (6.3 %) 11 (4.8 %) 3 (5.2 %) 10 (10.3 %) 17 (9.3 %)
24 5 (12.8 %) 7 (9.2 %) 15 (7.0 %) 5 (9.1 %) 10 (10.6 %) 21 (11.7 %)
36 6 (17.1 %) 15 (22.4 %) 23 (11.2 %) 5 (10.0 %) 11 (12.8 %) 32 (20.3 %)
a Cases in which vertebral fractures occurred within the first 6 months were eliminated
Table 3 Odds ratios of vertebral fracture incidence at 12, 24, or 36 months according to gains in hip or lumbar spine BMD at 6 months by
treatment with ibandronate and risedronate
Gain in hip BMD at 6 months Treatment duration Against B0 Odds ratio (95 % CI)
Ibandronate Risedronate
12 months [0 to B3 % 0.52 (0.20, 1.41) 0.79 (0.37, 1.70)
[3 % 0.40 (0.13, 1.21) 0.54 (0.22, 1.36)
24 months [0 to B3 % 0.55 (0.23, 1.31) 0.64 (0.32, 1.31)
[3 % 0.41 (0.15, 1.14) 0.41 (0.17, 1.00)
36 months [0 to B3 % 0.51 (0.24, 1.09) 0.69 (0.35, 1.33)
[3 % 0.47 (0.20, 1.09) 0.44 (0.20, 0.99)
Gain in lumbar spine BMD at 6 monthsa Treatment duration Against B0 Odds ratio (95 % CI)
Ibandronate Risedronate
12 months [0 to B3 % 0.87 (0.18, 4.16) 2.65 (0.67, 10.46)
[3 % 0.77 (0.18, 3.21) 2.31 (0.62, 8.65)
24 months [0 to B3 % 0.76 (0.20, 2.79) 1.46 (0.46, 4.68)
[3 % 0.70 (0.21, 2.29) 1.68 (0.57, 4.96)
36 months [0 to B3 % 1.54 (0.51, 4.63) 1.65 (0.52, 5.25)
[3 % 0.72 (0.25, 2.03) 3.01 (1.05, 8.64)
a Cases in which vertebral fractures occurred within the first 6 months were eliminated
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fractures [18]. The number of vertebral fracture events in
the risedronate group ([0 to B3, and [3 % lumbar spine
BMD increase) was greater than in the ibandronate group.
Those might be a part of the reasons why the odds ratios in
the risedronate group were over 1. However, further ana-
lysis of the individual cases is needed.
Many reports have said that BMD might be a factor
predictive of future fractures in general. Additionally,
when the BMD measurements of the lumbar spine, femoral
neck, femoral trochanter, and hip were compared, hip
BMD was reported to be better at predicting future inci-
dence of all fractures than was lumbar spine BMD [19].
BMD measurements in all sites including hip were per-
formed centrally at each time using DXA machine because
the MOVER study was a randomized multicenter study.
We examined the mean BMD values of each treatment
group in the study, however, least significant change or
coefficient of variation is important on BMD measurement.
In clinical practice, due to variability of hip BMD mea-
surement, there might be a difficulty to obtain the accurate
data even though the treatment would express the efficacy
at 6 months. The relationship between BMD in the first 6
months and the time-course of incidence of hip fractures
should also be investigated; however, we did not get any
information due to the low number of non-vertebral frac-
tures including hip that occurred in the MOVER study.
Our analysis did not show the contribution rate of BMD
gains to the expression of the anti-fracture efficacy in the
MOVER study. It has been reported previously [8] that
BMD gains by ibandronate would explain approximately
one-third (24–37 %) of ibandronate’s anti-fracture effi-
cacy. That contribution rate was derived from analysis of
the BONE and IV studies in which the annual cumulative
exposure (ACE) was under 5.5 mg. However, the ACE in
the MOVER study was 12 mg; thus, the contribution of
BMD gains in the MOVER study might be much bigger.
We intend to calculate the contribution of BMD gains in
future analysis.
Our current analysis indicated that greater gains of BMD
in the hip in a relatively short period of 6 months of
treatment were associated with a greater reduction in the
risk of future vertebral fracture incidence. In fact, the BMD
measurements using DXA machine are reimbursable every
4 month in Japan and the physicians like to measure BMD
to evaluate the treatment regimen. We, in Japan, suggest to
measure BMD after 6 months of therapy and keep to do
every 6 month. In case the BMD measurement is not
available or practical, the measurement of bone turnover
markers (BTMs) could be supportive. In these days, not
only physicians but also patients would discuss their lab-
oratory data including BMD or BTMs values together,
which is desirable to keep better adherence to therapy for
osteoporosis. If there is no gain in BMD, it is an
opportunity to re-assess the current therapy. To change
drug would be one of next options and to add another drug
would be also an alternative. The results suggest that the
hip BMD value at 6-month treatment might be a useful
predictor to prevent the future vertebral fracture incidence
and provide an opportunity to assess the treatment options.
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